Circulating Tumor DNA Provides a Sneak Peek into Treatment Responses in Non-Small Cell Lung Cancer.
Circulating Tumor DNA Provides a Sneak Peek into Treatment Responses in Non-Small Cell Lung Cancer.
复制标题
DOI：
10.1158/0008-5472.can-19-0231
复制
发表时间：
2019-03-15
期刊：
影响因子：
11.2
通讯作者：
中科院分区：
文献类型：
--
作者：
循环肿瘤DNA(CtDNA)作为一种非侵入性的诊断工具在指导肺癌患者的治疗方面具有很大的前景。Phallen及其同事和Anagnostou及其同事的两项研究分别将ctDNA的敏感测量与非小细胞肺癌(NSCLC)患者对酪氨酸激酶抑制剂(TKI)和免疫检查点抑制剂的临床反应相关联。总之，这些研究进一步强调了在接受靶向治疗和免疫治疗的非小细胞肺癌患者中进行连续ctDNA监测的潜在临床实用价值。
Circulating tumor DNA (ctDNA) holds great promise as a noninvasive diagnostic tool to guide treatment for patients with lung cancer. Two studies by Phallen and colleagues and Anagnostou and colleagues correlated sensitive measures of ctDNA with clinical responses to tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors, respectively, in patients with non–small cell lung cancer (NSCLC). Together, these studies further highlight the potential clinical utility of serial ctDNA monitoring in patients with NSCLC undergoing treatment with both targeted therapies and immunotherapies.